Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-10-11

Clinical Trial Update: Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating cetuximab standard versus dose-escalation in first-line colorectal cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Cetuximab (cetuximab)

Snippet

Sponsor: Universitaire Ziekenhuizen KU Leuven | Conditions: Colorectal Cancer | Phase 2 | Status: COMPLETED | Results posted: 2019-10-11